These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 35920789)
1. Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases. Ziv A; Heshin-Bekenstein M; Haviv R; Kivity S; Netzer D; Yaron S; Schur Y; Egert T; Egert Y; Sela Y; Hashkes PJ; Uziel Y Rheumatology (Oxford); 2023 Feb; 62(SI2):SI145-SI151. PubMed ID: 35920789 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569 [TBL] [Abstract][Full Text] [Related]
3. Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases. Raptis CE; Berger CT; Ciurea A; Andrey DO; Polysopoulos C; Lescuyer P; Maletic T; Riek M; Scherer A; von Loga I; Safford J; Lauper K; Möller B; Vuilleumier N; Finckh A; Rubbert-Roth A Front Immunol; 2022; 13():1016927. PubMed ID: 36311791 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of the CoronaVac and BNT162b2 Covid-19 vaccine in patients with inflammatory rheumatic diseases and healthy adults: comparison of different vaccines. Batıbay S; Ulucaköy RK; Günendi Z; Fidan I; Bozdayı G; Göğüş FN Inflammopharmacology; 2022 Dec; 30(6):2089-2096. PubMed ID: 36282425 [TBL] [Abstract][Full Text] [Related]
5. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study. Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376 [TBL] [Abstract][Full Text] [Related]
6. Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Heshin-Bekenstein M; Ziv A; Toplak N; Lazauskas S; Kadishevich D; Ben-Nun Yaari E; Miller-Barmak A; Butbul Aviel Y; Saiag E; Pel S; Elkayam O; Uziel Y; Furer V Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112731 [TBL] [Abstract][Full Text] [Related]
7. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Furer V; Zisman D; Kibari A; Rimar D; Paran Y; Elkayam O Rheumatology (Oxford); 2021 Oct; 60(SI):SI90-SI95. PubMed ID: 33848321 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors. Dimopoulou D; Tsolia MN; Spyridis N; Maritsi DN Rheumatology (Oxford); 2023 Feb; 62(SI2):SI205-SI209. PubMed ID: 35788275 [TBL] [Abstract][Full Text] [Related]
9. Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. Akgün Ö; Çakmak F; Guliyeva V; Demirkan FG; Tanatar A; Hançerli Torun S; Çin D; Meşe S; Ağaçfidan A; Aktay Ayaz N Rheumatology (Oxford); 2022 Nov; 61(11):4482-4490. PubMed ID: 35353139 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Barda N; Dagan N; Cohen C; Hernán MA; Lipsitch M; Kohane IS; Reis BY; Balicer RD Lancet; 2021 Dec; 398(10316):2093-2100. PubMed ID: 34756184 [TBL] [Abstract][Full Text] [Related]
11. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore. Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588 [TBL] [Abstract][Full Text] [Related]
12. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. Fleming-Dutra KE; Britton A; Shang N; Derado G; Link-Gelles R; Accorsi EK; Smith ZR; Miller J; Verani JR; Schrag SJ JAMA; 2022 Jun; 327(22):2210-2219. PubMed ID: 35560036 [TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. June Choe Y; Yi S; Hwang I; Kim J; Park YJ; Cho E; Jo M; Lee H; Hwa Choi E Vaccine; 2022 Jan; 40(5):691-694. PubMed ID: 35012777 [TBL] [Abstract][Full Text] [Related]
14. Humoral immunogenicity of COVID-19 vaccines in patients with inflammatory rheumatic diseases under treatment with Rituximab: a case-control study (COVID-19VacRTX). Schumacher F; Mrdenovic N; Scheicht D; Pons-Kühnemann J; Scheibelhut C; Strunk J Rheumatology (Oxford); 2022 Oct; 61(10):3912-3918. PubMed ID: 35094050 [TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis. Sibbel S; McKeon K; Luo J; Wendt K; Walker AG; Kelley T; Lazar R; Zywno ML; Connaire JJ; Tentori F; Young A; Brunelli SM J Am Soc Nephrol; 2022 Jan; 33(1):49-57. PubMed ID: 34789546 [TBL] [Abstract][Full Text] [Related]
16. Serological Response to BNT162b2 Anti-SARS-CoV-2 Vaccination in Patients with Inflammatory Rheumatic Diseases: Results From the RHEUVAX Cohort. Mauro D; Ciancio A; Di Vico C; Passariello L; Rozza G; Pasquale MD; Pantano I; Cannistrà C; Bucci L; Scriffignano S; Riccio F; Patrone M; Scalise G; Ruscitti P; Montemurro MV; Giordano A; Vietri MT; Ciccia F Front Immunol; 2022; 13():901055. PubMed ID: 35784360 [TBL] [Abstract][Full Text] [Related]
17. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F; PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992 [TBL] [Abstract][Full Text] [Related]
18. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
19. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
20. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]